Quality Appraisal of Ambulatory Oral Cephalosporin and Fluoroquinolone Use in the 16 German Federal States from 2014-2019.
antibiotic utilization
cephalosporins
fluoroquinolones
prescription rates
quality appraisal
regional differences
Journal
Antibiotics (Basel, Switzerland)
ISSN: 2079-6382
Titre abrégé: Antibiotics (Basel)
Pays: Switzerland
ID NLM: 101637404
Informations de publication
Date de publication:
08 Jul 2021
08 Jul 2021
Historique:
received:
14
06
2021
revised:
02
07
2021
accepted:
05
07
2021
entrez:
6
8
2021
pubmed:
7
8
2021
medline:
7
8
2021
Statut:
epublish
Résumé
Despite concerns about causing bacterial resistance and serious side effects, oral cephalosporins and fluoroquinolones are still frequently prescribed in Germany. We aimed to test a method for the detection of regional quality differences in the use of oral cephalosporins and fluoroquinolones and to apply this to the German federal states. Use of antibiotics from 2014-2019 was analyzed using dispensing data from community pharmacies claimed to the statutory health insurance (SHI) funds. Quality of regional antibiotic use in 2019 was assessed by calculating indicators based on defined daily doses per 1000 SHI-insured persons per day (DID). Oral cephalosporin and fluoroquinolone use was followed by linear regression analyses. The method used was suitable to find meaningful quality differences in ambulatory oral cephalosporin and fluoroquinolone use between the German federal states. In 2019, DID varied from 1.62 in Brandenburg to 3.17 in Rhineland-Palatinate for cephalosporins and from 0.47 in Brandenburg to 0.89 in Saarland for fluoroquinolones. The city-states Hamburg, Bremen, and Berlin showed highest quality with the applied indicator set. From 2014-2019, a significant decrease in utilization of oral cephalosporins was found in all federal states. During 2017-2019, all states showed a significant decline of fluoroquinolone use.
Sections du résumé
BACKGROUND
BACKGROUND
Despite concerns about causing bacterial resistance and serious side effects, oral cephalosporins and fluoroquinolones are still frequently prescribed in Germany. We aimed to test a method for the detection of regional quality differences in the use of oral cephalosporins and fluoroquinolones and to apply this to the German federal states.
METHODS
METHODS
Use of antibiotics from 2014-2019 was analyzed using dispensing data from community pharmacies claimed to the statutory health insurance (SHI) funds. Quality of regional antibiotic use in 2019 was assessed by calculating indicators based on defined daily doses per 1000 SHI-insured persons per day (DID). Oral cephalosporin and fluoroquinolone use was followed by linear regression analyses.
RESULTS
RESULTS
The method used was suitable to find meaningful quality differences in ambulatory oral cephalosporin and fluoroquinolone use between the German federal states. In 2019, DID varied from 1.62 in Brandenburg to 3.17 in Rhineland-Palatinate for cephalosporins and from 0.47 in Brandenburg to 0.89 in Saarland for fluoroquinolones. The city-states Hamburg, Bremen, and Berlin showed highest quality with the applied indicator set. From 2014-2019, a significant decrease in utilization of oral cephalosporins was found in all federal states. During 2017-2019, all states showed a significant decline of fluoroquinolone use.
Identifiants
pubmed: 34356753
pii: antibiotics10070831
doi: 10.3390/antibiotics10070831
pmc: PMC8300794
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
BMJ Open. 2021 Jan 15;11(1):e041218
pubmed: 33452190
Qual Saf Health Care. 2007 Dec;16(6):440-5
pubmed: 18055888
Proc Natl Acad Sci U S A. 2018 Apr 10;115(15):E3463-E3470
pubmed: 29581252
Euro Surveill. 2020 Aug;25(31):
pubmed: 32762794
Pharmacoepidemiol Drug Saf. 2018 Dec;27(12):1344-1355
pubmed: 30264894
J Antimicrob Chemother. 2011 Dec;66 Suppl 6:vi71-77
pubmed: 22096068
J Antimicrob Chemother. 2007 Sep;60(3):638-44
pubmed: 17626023
J Infect Chemother. 2016 May;22(5):319-26
pubmed: 26968486
Euro Surveill. 2010 Sep 02;15(35):
pubmed: 20822733
JAMA Intern Med. 2021 Jun 1;181(6):808-816
pubmed: 33871571
Dtsch Arztebl Int. 2020 Oct 9;117(41):679-686
pubmed: 33357337
Lancet. 2005 Feb 12-18;365(9459):579-87
pubmed: 15708101
Infection. 2006 Oct;34(5):269-73
pubmed: 17033751
Euro Surveill. 2010 Feb 04;15(5):
pubmed: 20144444
Dtsch Arztebl Int. 2009 Nov;106(48):783-8
pubmed: 20038980
CMAJ. 1999 Apr 6;160(7):1013-7
pubmed: 10207340
J Hum Hypertens. 2020 Oct 14;:
pubmed: 33057175
Dtsch Arztebl Int. 2016 Jul 1;113(26):454-9
pubmed: 27412990
J Clin Pharm Ther. 2018 Feb;43(1):59-64
pubmed: 28833324